Stock Groups

Activist investor Bluebell takes stake in GSK

[ad_1]

© Reuters. FILE PHOTO A GlaxoSmithKline facility is seen in Montrose (Scotland), Britain, October 22, 2018. Andy Buchanan/Pool via REUTERS/File Photo

(Reuters) – Activist investor Bluebell Capital Partners has taken a small stake in British pharmaceuticals group GlaxoSmithKline (NYSE:) in efforts to shake up top management, a Financial Times report said on Wednesday.

In a letter sent to GSK’s chairman Jonathan Symonds, Bluebell called for chief executive Emma Walmsley to reapply for her job as she would have “renewed credibility both internally and externally”, the FT report said.

GSK activist Elliott took a stake earlier in the year. This prompted a change of leadership at GSK.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs include futures, stocks, indexes and Forex. Prices are provided not by the exchanges. They are drawn from market makers. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]